None listed
Conditions
Interventions
None listed
Sponsors
Chonnam National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Adults (male or female) aged 18 years or older 2)Individuals diagnosed with dry eye disease accompanied by meibomian gland dysfunction (MGD) ? “Dry eye disease” is defined as meeting at least one of the following criteria: a) Presence of dry eye symptoms b) Schirmer test without topical anesthesia showing < 10 mm at 5 minutes ? “Meibomian gland dysfunction (MGD)” is defined as fulfilling (a) at least one of the following clinical findings and (b): a) Irregular lid margin, telangiectasia, meibomian orifice obstruction, or anterior/posterior displacement of the mucocutaneous junction b) Expression of turbid meibum upon meibomian gland compression 3) Individuals scheduled to undergo cosmetic radiofrequency facial treatment around the periocular region 4) Individuals who have voluntarily provided written informed consent after receiving an explanation of the study
Exclusion criteria
Exclusion criteria: 1) Fitzpatrick skin type V–VI 2) Use of photosensitizing medications (e.g., retinoids) or presence of photosensitive or vasoreactive dermatologic conditions (e.g., rosacea) 3) Presence of metallic implants or electronic implanted medical devices (e.g., pacemaker) in or near the treatment area 4) History of keloid formation or active dermatologic disease 5) Pregnant or breastfeeding women 6) Individuals with hypersensitivity or predicted adverse reactions to radiofrequency treatment (e.g., history of burns during RF treatment, moderate or severe neuralgia) 7) History of treatment with intense pulsed light (IPL) for meibomian gland dysfunction 8) History of ocular surgery (e.g., cataract surgery, eyelid surgery) within the past 3 months, or chronic contact lens wearers 9) Presence of hordeolum or other conditions likely to affect meibomian gland function 10) History of infectious ocular disease within the past 3 months 11) Use of glaucoma eye drops or systemic medications known to adversely affect dry eye within 2 weeks prior to the start of treatment 12) Change in dry eye medications within 1 month prior to the start of treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ocular Surface Disease Index (OSDI-6);tear film break-up time;basic tear secretion test;corneal staining score;meibomian gland function assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| tear film lipid layer imaging and thickness measurement | — |
Countries
Korea, Republic of
Contacts
Public ContactHyun Jee Kim
Chonnam National University Hospital
Outcome results
None listed